Evidence map›Paper›PMID 32302349›Full record

ArticlePloS one2020

Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis.

Fanny Pineau, Davide Caimmi, Milena Magalhães, Enora Fremy, Abdillah Mohamed, Laurent Mely, Sylvie Leroy, Marlène Murris, Mireille Claustres, Raphael Chiron and 1 more

2 registry-linked trialsAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02884622 nacompletednot on this map

DNA Methylation and Lung Disease in Cystic Fibrosis

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2013 to 2016Enrolled72ConditionsCystic FibrosisArmsnasal epithelial, Blood sampling
NCT02976714 nacompletednot on this map

Identification of Predictive Epigenetic Biomarkers of Lung Disease Severity in Cystic Fibrosis

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2016 to 2021Enrolled50ConditionsCystic FibrosisArmsspontaneous sputum
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. DNA Methylation atGenes · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fanny PineauEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.
Davide CaimmiCRCM, Arnaud de Villeneuve Hospital, Montpellier, France.
Milena MagalhãesEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.ORCID 0000-0002-1695-7515
Enora FremyEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.
Abdillah MohamedEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.ORCID 0000-0002-6042-7714
Laurent MelyCRCM, Renée Sabran Hospital, Hyères, France.
Sylvie LeroyCRCM, Pasteur Hospital, Nice, France.
Marlène MurrisCRCM, Larrey Hospital, Toulouse, France.
Mireille ClaustresEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.
Raphael ChironCRCM, Arnaud de Villeneuve Hospital, Montpellier, France.
Albertina De SarioEA7402, Laboratoire de Génétique de Maladies Rares (LGMR), University of Montpellier, Montpellier, France.ORCID 0000-0002-9997-1645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) is a rare genetic disease that affects the respiratory and digestive systems. Lung disease is variable among CF patients and associated with the development of comorbidities and chronic infections. The rate of lung function deterioration depends not only on the type of mutations in CFTR, the disease-causing gene, but also on modifier genes. In the present study, we aimed to identify genes and pathways that (i) contribute to the pathogenesis of cystic fibrosis and (ii) modulate the associated comorbidities. We profiled blood samples in CF patients and healthy controls and analyzed RNA-seq data with Weighted Gene Correlation Network Analysis (WGCNA). Interestingly, lung function, body mass index, the presence of diabetes, and chronic P. aeruginosa infections correlated with four modules of co-expressed genes. Detailed inspection of networks and hub genes pointed to cell adhesion, leukocyte trafficking and production of reactive oxygen species as central mechanisms in lung function decline and cystic fibrosis-related diabetes. Of note, we showed that blood is an informative surrogate tissue to study the contribution of inflammation to lung disease and diabetes in CF patients. Finally, we provided evidence that WGCNA is useful to analyze-omic datasets in rare genetic diseases as patient cohorts are inevitably small.

Indexed as

Genes, ModifierAdultComorbidityCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDiabetes MellitusFemaleHumansLungMaleMutationPseudomonas InfectionsTranscriptomeCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID32302349
PMCPMC7164665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.